Critically ill COVID-19 Patient Successfully Treated with Vitro Biopharma’s AlloRx Stem Cells®

Critically ill COVID-19 Patient Successfully Treated with Vitro Biopharma’s AlloRx Stem Cells®

September 21, 2020 0 Comments

Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, jointly with GIOSTAR – a San Diego, California-based institution headed by Dr. Anand Srivastava, a pioneer in stem cell science – announced the results of treatment of a critically ill COVID-19 patient with its lead clinical product AlloRx Stem Cells®.

Read More

Vitro Biopharma Signs MOU with GIOSTAR for COVID-19 IND Using AlloRx Stem Cells

Vitro Biopharma Signs MOU with GIOSTAR for COVID-19 IND Using AlloRx Stem Cells

September 21, 2020 0 Comments

Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro entered into an exclusive Memorandum of Understanding (MOU) with Global Institute of Stem Cell Therapy and Research, Inc. (“GIOSTAR”) a leading stem cell research institute based in San Diego, California to jointly partner together for a COVID-19 Investigational New Drug 

Read More

Vitro Biopharma Submits IND Application to FDA for AlloRx Stem Cell(R) Therapy of COVID-19

Vitro Biopharma Submits IND Application to FDA for AlloRx Stem Cell(R) Therapy of COVID-19

September 21, 2020 0 Comments

Dr. Jim Musick, Ph.D., CEO said, “We are very pleased to have submitted our IND using our expanded regulatory team, including a renown regulatory expert in FDA clinical trial management. We are establishing strong communication channels with FDA officials to facilitate and expedite review of our application as well as subsequent steps to gain full FDA approval of AlloRx Stem Cells®. 

Read More